Katherine Matthay

18PUBLICATIONS
66CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyInfant and child healthRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 23, 2026
Factors Impacting Overall Survival Post-Relapse in High-Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019.

|May 12, 2026
Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I-Metaiodobenzylguanidine Radiotherapy in the Anti-GD2 Immunotherapy Era.

|Dec 23, 2025
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.

Wendy B London, Gabriela Villanueva, Derek Shyr

|Jun 23, 2025
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Thomas Cash, Araz Marachelian, Steven G DuBois

|Jun 01, 2024
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.

Erin K Barr, Arlene Naranjo, Clare J Twist

|May 01, 2024
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.

Prerna Kumar, Victoria W Willard, Leanne Embry

Pageof 3

Frequent Collaborators

8 joint publications

Steven G DuBois

4 joint publications

Susan L Cohn

4 joint publications

Julie R Park

4 joint publications

Barry Shulkin